Research programme: cancer therapeutics - Apceth/University of Cologne

Drug Profile

Research programme: cancer therapeutics - Apceth/University of Cologne

Alternative Names: CART cells - Apceth/University of Cologne; Genetically-modified mesenchymal stem cells - Apceth/University of Cologne; gmMSCs - Apceth/University of Cologne

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apceth; University of Cologne
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jul 2015 Apceth and the University of Cologne agree to co-develop immunotherapies in Germany for Cancer
  • 10 Jul 2015 Preclinical trials in Cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top